Document is current
Any future updates will be listed below
-
Authors
Feng, Weiran https://orcid.org/0000-0002-3422-4964
Ladewig, Erik
Lange, Matthew https://orcid.org/0009-0008-7526-2140
Salsabeel, Nazifa
Zhao, Huiyong
Lee, Young Sun
Gopalan, Anuradha
Luo, Hanzhi
Kang, Wenfei
Fan, Ning
Rosiek, Eric https://orcid.org/0000-0001-6355-1457
de Stanchina, Elisa
Chen, Yu https://orcid.org/0000-0002-0171-3884
Carver, Brett S. https://orcid.org/0000-0001-5165-3544
Leslie, Christina S. https://orcid.org/0000-0002-4571-5910
Sawyers, Charles L. https://orcid.org/0000-0003-4955-6475
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA193837, CA092629, CA224079, CA155169, 1K99CA276888-01, CA274492, CA008748, DK128602-03, CA008748, CA008748, CA008748, CA008748, CA224079, CA257811, CA274492)
Howard Hughes Medical Institute
U.S. Department of Defense (W81XWH-19-1-0323, W81XWH-21-1-0431)
Prostate Cancer Foundation (20YOUN22)
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 8 July 2025
First Online: 26 August 2025
Change Date: 29 August 2025
Change Type: Update
Change Details: In the version of the article initially published, Weiran Feng and Erik Ladewig were not listed as equal contributors and the sentence “Matthew Lange, Nazifa Salsabeela and Huiyong Zhao are co-second authors” was missing from the Author contributions. These omissions have now been corrected in the HTML and PDF versions of the article.
Competing interests
: C.L.S. served on the Board of Directors of Novartis (2013–2025), is a co-founder of ORIC Pharmaceuticals and is co-inventor of enzalutamide and apalutamide. He is a science advisor to Beigene, Blueprint, CellCarta, Column Group, Foghorn, Housey Pharma, Nextech and PMV. Y.C. received research funding from Foghorn therapeutics, consulted for Fog Pharma and Belharra Therapeutics and has stock ownership of ORIC Pharmaceuticals. The other authors declare no competing interests.
